purpose united kingdom NUMBER patients asthma homozygous beta2adrenoceptor polymorphism predisposes downregulation desensitization assessed effects adding treatment beta2agonist inhaled formoterol NUMBER microg twice daily leukotriene receptor antagonist oral zafirlukast NUMBER mg twice daily inhaled corticosteroid therapy patients genotypesubjects methods enrolled NUMBER patients mild moderate asthma treated inhaled corticosteroids patients randomly assigned receive treatments placebo zafirlukast formoterol addition inhaled corticosteroids NUMBER week crossover fashion separated placebo washout period measurements bronchoprotection measured provocative dose methacholine produced NUMBER decline forced expiratory volume NUMBER second fev1 exhaled nitric oxide surrogate marker airway inflammation symptoms treatment NUMBER hours dose treatmentresults formoterol zafirlukast equally effective maintaining asthma control compared placebo geometric difference methacholine provocative dose NUMBER confidence interval ci zafirlukast NUMBER ci formoterol compared placebo zafirlukast caused significant suppression exhaled nitric oxide difference geometric mean values NUMBER ci formoterol did difference NUMBER ci diary cards showed significant p NUMBER improvements peak flow formoterol morning evening zafirlukast evening compared placeboconclusions formoterol zafirlukast maintained asthma control patients genetically predisposed fare worse beta2agonists reduction exhaled nitric oxide zafirlukast suggests effects addition seen inhaled corticosteroids glycine NUMBER agonist induced beta2 adrenoceptor long acting NUMBER week run mean fold NUMBER fold NUMBER NUMBER fold NUMBER fold NUMBER NUMBER fold NUMBER fold NUMBER NUMBER fold NUMBER fold NUMBER NUMBER fold long acting anti inflammatory